Linezolid

Restricted
C difficile risk
Low
Oral Bioavailability
Excellent
Cost
IV:$$$$$$ PO:$$$$$

Dosing

600mg PO/IV Q12h

600mg PO/IV q12h

General Information

Antimicrobial Stewardship approved criteria must be indicated at ORDER ENTRY.

Approved Indications:

  1. Documented VRE from a non-urine source
  2. S.aureus with high vancomycin MIC (2 mcg/ml)
  3. Documented vancomycin allergy - NOT Red Man's
  4. Vancomycin failure of therapy (>= 5 days)
  5. Unable to reach target vancomycin trough
  6. PO Therapy - MRSA or VRE (non-urine)

Targeted or empiric therapy for gram positive infections including skin and soft tissue, and pneumonia.

Covers MRSA and VRE.

CBC at least once/week

Visual testing for therapy >3 months or if symptoms develop on therapy.

  • Serotonin syndrome

  • Rash

  • Elevated liver enzymes

  • Lactic acidosis

  • Myelosuppression (usually with >2weeks therapy)- reversible

  • Peripheral/optic neuropathy with prolonged courses

SSRI and other serotonergics/MAOIs - Increased risk of serotonin syndrome.

Rifampin decreases linezolid levels.

Antimicrobial class: Oxazolidinone

Pregnancy category: C

Average serum half life: 5 hours

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic